Biocon Biologics

Biocon Biologics secures US FDA approval for Biosimilar Bevacizumab, JOBEVNE

Read more

Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis

Read more

Biocon Biologics launches YESINTEK, a Stelara biosimilar, in the United States

Read more

Biocon’s S&P Global ESG Score improves to 69 for 2024

Read more

US FDA classifies Biocon Biologics site as VAI

Read more

Biocon Biologics completes one year as an integrated global biosimilars enterprise

Read more

Innovation, partnerships and best practices: Priorities for biopharma in 2025

Read more

Biocon Biologics’ Ustekinumab Biosimilar receives positive CHMP opinion

Read more

Biocon Biologics receives FDA approval for biosimilar YESINTEK

Read more

Biocon Biologics supports Diabetes Africa to drive progress in embedding specialist nurses in diabetes care in Ethiopia

Read more